APC and colorectal carcinoma: These results not only demonstrate the feasibility of exploiting the APC-Asef interaction as a target against metastatic CRC for drug discovery, but also establish a new pharmacological paradigm for the use of peptides/peptidomimetics as inhibitors of protein–protein interactions.